Supplementary Figures S1-S4 and Legends from Biodistribution and Targeting of Anti-5T4 Antibody–Drug Conjugate Using Fluorescence Molecular Tomography

Authors:
  • AGAnand Giddabasappa
    Anand Giddabasappa
  • VGVijay R. Gupta
    Vijay R. Gupta
  • RNRand Norberg
    Rand Norberg
  • PGParul Gupta
    Parul Gupta
  • MSMary E. Spilker
    Mary E. Spilker
  • JWJoann Wentland
    Joann Wentland
  • BRBrian Rago
    Brian Rago
  • JEJeetendra Eswaraka
    Jeetendra Eswaraka
  • MLMauricio Leal
    Mauricio Leal
  • PSPuja Sapra
    Puja Sapra

Abstract
Supplemental Figure 1: Standard curve of VT680 showing the 3-D quantitation and linearity by FMT imaging; Supplemental Figure 2: Evaluation of VT680 conjugated 5T4-Ab and 5T4-ADC; Supplemental Figure 3: Determination of antibody binding capacity (ABC) and receptor saturation in H1975 and MDA-MB-468 cells by flow cytometry; Supplemental Figure 4: Ex vivo FMT imaging showing the accumulation of 5T4-Ab-VT680, 5T4-ADC-VT680, Isotype control-Ab-VT680 and VT680 alone 48 h post-injection in tumor (A) and liver (B).